daurismo
pfizer europe ma eeig - glasdegib maleate - leukemija, myeloid, akutna - antineoplastična sredstva - daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (aml) in adult patients who are not candidates for standard induction chemotherapy.
vanflyta
daiichi sankyo europe gmbh - quizartinib dihydrochloride - leukemija, myeloid - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.
novantrone 2 mg/ml koncentrat za raztopino za injiciranje/infundiranje
meda pharma gmbh & co. kg - mitoksantron - koncentrat za raztopino za injiciranje/infundiranje - mitoksantron 20 mg / 1 ml - mitoksantron
enrylaze
jazz pharmaceuticals ireland limited - crisantaspase - predkroglomerna limfoblastna levkemija limfoma - antineoplastična sredstva - enrylaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia (all) and lymphoblastic lymphoma (lbl) in adult and paediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to e. coli-derived asparaginase.
kymriah
novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - drugi antineoplastiki - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.
dacogen
janssen-cilag international n.v. - decitabin - leukemija, myeloid - antineoplastična sredstva - zdravljenje odraslih bolnikov z novo diagnosticirano de novo ali sekundarno akutno mieloično levkemijo (aml), v skladu s klasifikacijo svetovne zdravstvene organizacije (who), ki niso kandidati za standardno indukcijsko kemoterapijo.
spectrila
medac gesellschaft fuer klinische spezialpraeparate mbh - asparaginaza - predkroglomerna limfoblastna levkemija limfoma - antineoplastična sredstva - spectrila je naveden kot sestavni del antineoplastic kombinirano zdravljenje za zdravljenje akutno limfoblastno levkemijo, (vse), pri pediatričnih bolnikih od rojstva do 18 let in odrasli.
fludara 10 mg filmsko obložene tablete
genzyme europe b.v. - fludarabin - filmsko obložena tableta - fludarabin 7,9 mg / 1 tableta - fludarabin
fludara 10 mg filmsko obložene tablete
genzyme europe b.v. - fludarabin - filmsko obložena tableta - fludarabin 7,9 mg / 1 tableta - fludarabin
fludarabin teva 25 mg/ml koncentrat za raztopino za injiciranje ali infundiranje
teva pharma b.v. - fludarabin - koncentrat za raztopino za injiciranje/infundiranje - fludarabin 19,75 mg / 1 ml - fludarabin